ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Abdera Therapeutics, a radiopharmaceutical start-up, has raised $142 million in series A and B financing. The series A round was led by Versant Ventures and Amplitude Ventures; venBio partners led the series B round. Abdera’s potential medicines feature heavy-chain-only antibodies that target cancer cells and are linked to tumor-killing radioisotopes. The company anticipates submitting an investigational new drug application to the US Food and Drug Administration next year for its lead product candidate, which is for small-cell lung cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X